Targeting soluble amyloid-beta oligomers with a novel nanobody

Area of Science:

• Neuroscience
• Biochemistry
• Immunology

Background:

• The amyloid cascade hypothesis implicates amyloid plaques and Tau tangles in Alzheimer's disease (AD).
• Soluble amyloid-β oligomers (SAβOs) accumulate early in AD pathogenesis, preceding plaque formation and causing cognitive deficits.
• The distinct roles and localization of SAβOs versus amyloid plaques require further investigation for targeted AD therapies.

Purpose of the Study:

• To develop and characterize a novel nanobody targeting SAβOs.
• To evaluate the diagnostic and potential theragnostic capabilities of the anti-SAβO nanobody in an Alzheimer's disease model.

Main Methods:

• Generation of a novel anti-SAβO nanobody (E3) using an alpaca immunization model.
• In vitro and in vivo characterization of the E3 nanobody in 5XFAD transgenic mice.
• Fluorescein (FAM)-labeling of the E3 nanobody for imaging and biodistribution studies.

Main Results:

• The E3 nanobody successfully recognized both SAβOs and amyloid-β plaques.
• The E3 nanobody demonstrated blood-brain barrier penetration and binding to brain amyloid species in vivo.
• Imaging revealed distinct spatial distributions: SAβOs associated with neurons and plaques in the extracellular matrix.

Conclusions:

• The developed E3 nanobody effectively targets SAβOs and amyloid plaques.
• The E3 nanobody exhibits potential as a diagnostic imaging agent for Alzheimer's disease.
• This nanobody holds promise for future theragnostic applications in Alzheimer's disease treatment.